IL288609B - Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog - Google Patents

Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog

Info

Publication number
IL288609B
IL288609B IL288609A IL28860921A IL288609B IL 288609 B IL288609 B IL 288609B IL 288609 A IL288609 A IL 288609A IL 28860921 A IL28860921 A IL 28860921A IL 288609 B IL288609 B IL 288609B
Authority
IL
Israel
Prior art keywords
reflog
surfactants
artificial
production
methods
Prior art date
Application number
IL288609A
Other languages
Hebrew (he)
Other versions
IL288609B2 (en
IL288609A (en
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of IL288609A publication Critical patent/IL288609A/en
Publication of IL288609B publication Critical patent/IL288609B/en
Publication of IL288609B2 publication Critical patent/IL288609B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
IL288609A 2014-11-05 2021-12-02 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog IL288609B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075864P 2014-11-05 2014-11-05
US201462075866P 2014-11-05 2014-11-05
PCT/US2015/059349 WO2016073798A1 (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Publications (3)

Publication Number Publication Date
IL288609A IL288609A (en) 2022-02-01
IL288609B true IL288609B (en) 2022-10-01
IL288609B2 IL288609B2 (en) 2023-02-01

Family

ID=54697646

Family Applications (7)

Application Number Title Priority Date Filing Date
IL283699A IL283699B (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL296246A IL296246A (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL295292A IL295292B2 (en) 2014-11-05 2015-11-05 Methods and preparations related to artificial nanocarriers with rapamycin in a supersaturated steady state
IL251620A IL251620B (en) 2014-11-05 2017-04-06 Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog
IL251622A IL251622B (en) 2014-11-05 2017-04-06 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL280518A IL280518B (en) 2014-11-05 2021-01-31 Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog
IL288609A IL288609B2 (en) 2014-11-05 2021-12-02 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Family Applications Before (6)

Application Number Title Priority Date Filing Date
IL283699A IL283699B (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL296246A IL296246A (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL295292A IL295292B2 (en) 2014-11-05 2015-11-05 Methods and preparations related to artificial nanocarriers with rapamycin in a supersaturated steady state
IL251620A IL251620B (en) 2014-11-05 2017-04-06 Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog
IL251622A IL251622B (en) 2014-11-05 2017-04-06 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL280518A IL280518B (en) 2014-11-05 2021-01-31 Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog

Country Status (23)

Country Link
US (3) US20160128987A1 (en)
EP (6) EP3215133B1 (en)
JP (5) JP6912377B2 (en)
KR (2) KR102656139B1 (en)
CN (5) CN107072964A (en)
AU (4) AU2015342968B2 (en)
BR (3) BR122021025344B1 (en)
CA (2) CA2966850C (en)
CY (1) CY1124418T1 (en)
DK (4) DK3215192T3 (en)
EA (2) EA201790978A1 (en)
ES (4) ES2865375T3 (en)
FI (2) FI3834823T3 (en)
HR (1) HRP20210098T1 (en)
HU (4) HUE067697T2 (en)
IL (7) IL283699B (en)
LT (1) LT3215133T (en)
MX (4) MX386982B (en)
PL (1) PL3215133T3 (en)
PT (1) PT3215133T (en)
RS (1) RS61359B1 (en)
SI (1) SI3215133T1 (en)
WO (2) WO2016073799A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022699B1 (en) 2009-05-27 2016-02-29 Селекта Байосайенсиз, Инк. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
CN106177940A (en) 2010-05-26 2016-12-07 西莱克塔生物科技公司 The dosage choice of the synthesis nano-carrier containing adjuvant
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
AU2012249553A1 (en) 2011-04-29 2013-10-24 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
KR20140050698A (en) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
MX2015015231A (en) 2013-05-03 2016-07-06 Selecta Biosciences Inc METHODS AND COMPOSITIONS TO IMPROVE CD4 + REGULATOR T CELLS.
JP6248263B2 (en) * 2013-08-20 2017-12-20 サンノプコ株式会社 Additive for bioethanol fermentation process and method for producing bioethanol
IL292575A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US10125378B2 (en) * 2015-02-17 2018-11-13 San Nopco Ltd. Additive for bioethanol fermentation process and method for producing bioethanol
WO2016176462A1 (en) * 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
WO2017156513A1 (en) 2016-03-11 2017-09-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
KR102341902B1 (en) * 2016-09-09 2021-12-21 카오카부시키가이샤 Dicarboxylic acid crystal and method for producing same
CN109922819A (en) 2016-09-27 2019-06-21 西莱克塔生物科技公司 Recombinant immunotoxin for treating cancer
WO2018129268A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
SG11202107922QA (en) * 2019-01-24 2021-08-30 Generation Bio Co Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
AU2020284555A1 (en) 2019-05-28 2021-12-23 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CA3138071A1 (en) 2019-06-04 2020-12-10 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
MX2022004759A (en) * 2019-10-21 2022-08-19 Selecta Biosciences Inc Methods and compositions for treating liver diseases and disorders.
CN118384281A (en) 2019-11-08 2024-07-26 西莱克塔生物科技公司 Formulations and dosages of pegylated uricase
MX2022010568A (en) 2020-02-26 2022-11-30 Selecta Biosciences Inc Methods and compositions using synthetic nanocarriers comprising immunosuppressant.
BR112022018070A2 (en) * 2020-03-11 2022-10-25 Selecta Biosciences Inc METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOVEHICLES
CN115916193A (en) * 2020-04-14 2023-04-04 西莱克塔生物科技公司 Methods and compositions for inducing autophagy
WO2022098901A1 (en) 2020-11-04 2022-05-12 Selecta Biosciences, Inc. Compositions for reducing immune responses against immunoglobulin proteases
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
KR102304785B1 (en) 2021-03-26 2021-09-24 (주)진성티앤피 Method for manufacturing parts of precision optical devices
MX2023011930A (en) 2021-04-09 2024-03-11 Selecta Biosciences Inc SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR ANTAGONISTS TO IMPROVE IMMUNE TOLERANCE.
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
JP2024539646A (en) 2021-10-12 2024-10-29 カーティザン セラピューティクス，インコーポレーテッド Viral Vector Dosing Protocol
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
AU2023321906A1 (en) 2022-08-11 2025-03-27 Cartesian Therapeutics, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
TWI877967B (en) * 2023-12-28 2025-03-21 訊聯生物科技股份有限公司 Composition comprising microrna and nanocarrier, medicament comprising the same and use thereof
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
AU5068999A (en) 1998-07-31 2000-02-21 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
DE69930753D1 (en) * 1998-09-01 2006-05-18 Elan Corp Plc Dublin METHOD FOR THE INDUCTION OF THE CELLULAR IMMUNE RESPONSE AND PARENTERAL VACCINE COMPOSITIONS THEREFOR
JP4751556B2 (en) 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド Nanocapsule encapsulation system and method
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20050232984A1 (en) 2002-08-23 2005-10-20 Heinrich Haas Non-vesicular cationic lipid formulations
CN1886100A (en) * 2003-11-14 2006-12-27 阿尔萨公司 Surfactant-based gels as injectable sustained drug delivery vehicles
US20050260260A1 (en) 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
MX350501B (en) 2007-10-12 2017-09-07 Massachusetts Inst Technology Vaccine nanotechnology.
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8206747B2 (en) * 2008-06-16 2012-06-26 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
CN101676291B (en) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 Rapamycin carbonate analog, pharmaceutical composition thereof, and preparation method and uses thereof
ES2776126T3 (en) * 2008-12-15 2020-07-29 Pfizer Long-circulating nanoparticles for sustained release of therapeutic agents
KR101267813B1 (en) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 An injectable composition comprising polymeric nanoparticles containing rapamycin with an improved water solubility and a method for preparing the same, and an anticancer composition comprising the same for a combination therapy with radiation
CN103179955B (en) * 2010-09-14 2016-08-03 纳诺洛吉卡股份公司 Supersaturated release excipients for poorly water soluble pharmaceutical and cosmetic active ingredients
WO2012059936A1 (en) * 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
AU2012249553A1 (en) * 2011-04-29 2013-10-24 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
CN102793674B (en) * 2011-05-26 2014-11-26 澳门科技大学 Triptolide solid lipid nanoparticles and preparation method and application thereof
AU2012323937A1 (en) 2011-10-14 2014-06-05 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
TWI439288B (en) * 2012-10-05 2014-06-01 Univ China Medical Medicinal carriers and preparation method and uses thereof
CN102871966B (en) * 2012-10-19 2013-11-20 东南大学 Nano drug carrier particles for improving bioavailability of rapamycin and preparation method thereof

Also Published As

Publication number Publication date
CA2966852C (en) 2024-01-02
MX2017005903A (en) 2017-06-27
IL251620B (en) 2021-02-28
ES2977259T3 (en) 2024-08-21
AU2015342969B2 (en) 2021-05-27
JP2017537081A (en) 2017-12-14
SI3215133T1 (en) 2021-07-30
EP3215133B1 (en) 2020-10-28
JP2017533243A (en) 2017-11-09
PL3215133T3 (en) 2021-06-14
IL288609B2 (en) 2023-02-01
BR112017008720A2 (en) 2017-12-19
KR102601922B1 (en) 2023-11-15
KR20170081660A (en) 2017-07-12
EP4356910A2 (en) 2024-04-24
CN107072964A (en) 2017-08-18
AU2015342968A1 (en) 2017-04-27
CN107072965A (en) 2017-08-18
CN115212186A (en) 2022-10-21
WO2016073799A1 (en) 2016-05-12
IL283699B (en) 2022-09-01
MX2017005904A (en) 2017-06-27
ES2977158T3 (en) 2024-08-20
JP2023169893A (en) 2023-11-30
CN113244191A (en) 2021-08-13
AU2021209202A1 (en) 2021-08-19
IL251622B (en) 2021-06-30
EP3215133A1 (en) 2017-09-13
AU2021209204A1 (en) 2021-08-19
EP3906918A1 (en) 2021-11-10
EP3834823A1 (en) 2021-06-16
IL295292A (en) 2022-10-01
BR112017008499B1 (en) 2023-10-03
HUE067697T2 (en) 2024-11-28
IL295292B2 (en) 2024-10-01
ES2865375T3 (en) 2021-10-15
CN115212187A (en) 2022-10-21
WO2016073799A9 (en) 2016-12-08
JP6912377B2 (en) 2021-08-04
US20160128987A1 (en) 2016-05-12
LT3215133T (en) 2021-02-25
DK3906918T3 (en) 2024-04-08
EP3215192A1 (en) 2017-09-13
JP2022173236A (en) 2022-11-18
IL288609A (en) 2022-02-01
EP4360633A2 (en) 2024-05-01
HUE053094T2 (en) 2021-06-28
CN107072965B (en) 2021-05-11
MX386982B (en) 2025-03-19
MX2021012273A (en) 2021-11-12
US20160128986A1 (en) 2016-05-12
CA2966852A1 (en) 2016-05-12
DK3215133T3 (en) 2021-02-01
CY1124418T1 (en) 2022-07-22
CA2966850A1 (en) 2016-05-12
DK3834823T3 (en) 2024-04-08
IL280518A (en) 2021-03-01
CA2966850C (en) 2024-03-26
US20250152561A1 (en) 2025-05-15
EA201790977A1 (en) 2017-10-31
EP4356910A3 (en) 2024-05-22
JP2021143180A (en) 2021-09-24
IL280518B (en) 2022-01-01
DK3215192T3 (en) 2021-05-03
WO2016073798A1 (en) 2016-05-12
BR112017008499A2 (en) 2017-12-26
EP4360633A3 (en) 2024-05-22
ES2846809T3 (en) 2021-07-29
AU2021209202B2 (en) 2023-11-30
PT3215133T (en) 2021-01-29
HRP20210098T1 (en) 2021-03-05
AU2015342969A1 (en) 2017-04-27
HUE054894T2 (en) 2021-10-28
EP3215192A4 (en) 2018-05-02
FI3834823T3 (en) 2024-04-02
BR122021025344B1 (en) 2024-02-20
IL251620A0 (en) 2017-06-29
IL295292B1 (en) 2024-06-01
IL296246A (en) 2022-11-01
JP7218089B2 (en) 2023-02-06
RS61359B1 (en) 2021-02-26
KR102656139B1 (en) 2024-04-11
FI3906918T3 (en) 2024-04-04
EA201790978A1 (en) 2017-09-29
IL283699A (en) 2021-07-29
AU2015342968B2 (en) 2021-05-27
HUE066099T2 (en) 2024-07-28
IL251622A0 (en) 2017-06-29
EP3906918B1 (en) 2024-01-03
MX2021006698A (en) 2021-07-07
MX383295B (en) 2025-03-13
EP3215192B1 (en) 2021-02-17
KR20170081659A (en) 2017-07-12
EP3834823B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
IL288609B (en) Methods and compositions related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog
FIC20250034I1 (en) O-deuterated atropine and in particular the deuterohemisulphate salt of O-deuterated atropine
IL280905A (en) Use of erythrohydroxybibopropion to increase drug level in plasma
IL273979A (en) Methods of producing modified natural killer cells and methods of use
CL2016002416A1 (en) Stable compositions of iodine not in complex and methods of use
IL258666A (en) Natural killer cells and ilc3 cells and their use
DK3215611T3 (en) Peptide-Mediated Administration of RNA-Guided ENDONUCLEASE IN CELLS
SI2943078T1 (en) Methods and composition of ingested products
PT3066201T (en) METHODS AND COMPOSITIONS RELATED TO CRISPR WITH REGULATORY RANGES
PT3102189T (en) COMPOSITION AND METHOD TO IMPROVE SLEEP
IL255307B (en) Compositions of 1ttp and their uses in 2cln disease
HRP20182134T1 (en) TRIASINE COMPOUND AND ITS USE IN MEDICAL PURPOSES
SI3102185T1 (en) Nanosuspension of natural materials and the process of its preparation
ZA201804773B (en) Use of emulsifier in collector composition
IL251957A0 (en) Il-12 compositions and methods of use in hematopoietic recovery
ZA201603197B (en) Stable aqueous composition of neutral collectors and their use in mineral benefication processes
PL3157354T3 (en) COMPOSITION IN THE FORM OF COMPACTED PARTICLES AND THEIR APPLICATION
IL246711A0 (en) Bioactive heme-haloperoxidase compositions and methods of their use
FR3025698B1 (en) NEW USES OF CARBONIC ESTERS OF GLYCEROL IN AGRICULTURE
HRP20190041T1 (en) INSTALLATIONS TO ENCOURAGE THE INTEGRATION OF SOFT AND SOLID TISSUE
GB2527909B (en) Improvements in and relating to imaging of the eye
UY4426S (en) ORNAMENTAL PATTERN OF GOFRADO CIRCLES TYPE TO BE USED IN ABSORBENT ITEMS
AU358709S (en) Climbing frames [play equipment]
TH1601001966A (en) Dihydroxyalkyl-substituted polygalactomannan, and method of preparation and how to use those substances
GB201401296D0 (en) Bernard's theory of creation in nature applied to life and its sciences